全文获取类型
收费全文 | 385篇 |
免费 | 43篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 17篇 |
妇产科学 | 3篇 |
基础医学 | 68篇 |
口腔科学 | 3篇 |
临床医学 | 51篇 |
内科学 | 109篇 |
皮肤病学 | 8篇 |
神经病学 | 25篇 |
特种医学 | 12篇 |
外科学 | 26篇 |
综合类 | 5篇 |
预防医学 | 45篇 |
眼科学 | 3篇 |
药学 | 18篇 |
肿瘤学 | 21篇 |
出版年
2023年 | 7篇 |
2022年 | 9篇 |
2021年 | 12篇 |
2020年 | 7篇 |
2019年 | 7篇 |
2018年 | 14篇 |
2017年 | 10篇 |
2016年 | 7篇 |
2015年 | 11篇 |
2014年 | 14篇 |
2013年 | 19篇 |
2012年 | 26篇 |
2011年 | 21篇 |
2010年 | 15篇 |
2009年 | 11篇 |
2008年 | 9篇 |
2007年 | 15篇 |
2006年 | 11篇 |
2005年 | 8篇 |
2004年 | 17篇 |
2003年 | 7篇 |
2002年 | 8篇 |
2000年 | 3篇 |
1999年 | 3篇 |
1997年 | 5篇 |
1996年 | 6篇 |
1995年 | 2篇 |
1994年 | 6篇 |
1993年 | 6篇 |
1992年 | 10篇 |
1991年 | 8篇 |
1990年 | 6篇 |
1989年 | 11篇 |
1988年 | 11篇 |
1987年 | 4篇 |
1986年 | 10篇 |
1985年 | 4篇 |
1984年 | 12篇 |
1983年 | 2篇 |
1979年 | 6篇 |
1974年 | 2篇 |
1973年 | 4篇 |
1972年 | 2篇 |
1970年 | 2篇 |
1969年 | 5篇 |
1968年 | 2篇 |
1967年 | 2篇 |
1966年 | 6篇 |
1965年 | 4篇 |
1945年 | 2篇 |
排序方式: 共有428条查询结果,搜索用时 796 毫秒
121.
Wilmot S 《Medicine, health care, and philosophy》2000,3(2):139-146
The question of corporate moral responsibility – of whether it makes sense to hold an organisation corporately morally responsible
for its actions,rather than holding responsible the individuals who contributed to that action – has been debated over a number
of years in the business ethics literature. However, it has had little attention in the world of health care ethics. Health
care in the United Kingdom(UK) is becoming an increasingly corporate responsibility, so the issue is increasingly relevant
in the health care context, and it is worth considering whether the specific nature of health care raises special questions
around corporate moral responsibility. For instance, corporate responsibility has usually been considered in the context of
private corporations, and the organisations of health care in the UK are mainly state bodies. However, there is enough similarity
in relevant respects between state organisations and private corporations, for the question of corporate responsibility to
be equally applicable. Also, health care is characterised by professions with their own systems of ethical regulation. However,
this feature does not seriously diminish the importance of the corporate responsibility issue, and the importance of the latter
is enhanced by recent developments. But there is one major area of difference. Health care, as an activity with an intrinsically
moral goal, differs importantly from commercial activities that are essentially a moral, in that it narrows the range of opportunities
for corporate wrongdoing, and also makes such organisations more difficult to punish
This revised version was published online in July 2006 with corrections to the Cover Date. 相似文献
122.
123.
We have had experience with 260 prenatal diagnosis cases for the fragile X syndrome [fra(X)]; amniotic fluid was received in 230. There was a documented family history of fra(X) in 148 amniotic fluid cases. Our sample includes 91 males. Eleven were correctly identified as fra(X)-positive and 2 were false-negative. Eight of 57 females were fra(X) positive and one was a false-negative. CVS were received in 21 cases with a family history of fra(X), and there were 2 positive results in females and 3 false-negative results in males which were ultimately detected by means of molecular analysis or a subsequent amniotic fluid specimen. RFLPs were utilized in 29 cases (amniotic fluid and CVS); RFLPs identified 2 false-negative cytogenetic results in CVS. Two male fetuses were found to have a high probability of being affected by means of RFLPs, but on the basis of prenatal and postnatal negative fra(X) cytogenetic results and subsequent normal growth and development, they are either unaffected transmitting males or are double recombinants. Three female fetuses were also found to be cytogenetically negative in CVS but had a 90%, 93%, and 99% probability of being affected by RFLPs. On the basis of the data, it can be concluded: 1. Amniotic fluid experience is adequate to eliminate the "experimental" designation providing the limitations are understood and an experienced laboratory is involved. 2. Chorionic villus cells for cytogenetic analysis should still be considered experimental. 3. Negative results with CVS should be confirmed by molecular methods and/or by cytogenetic analysis of another tissue. 4. Multiple approaches can maximize reliability of fra(X) prenatal diagnosis. 相似文献
124.
125.
126.
127.
Z A Arlin E J Feldman T Ahmed D Liebowitz L R Shapiro P L Wilmot 《Acta haematologica》1989,81(4):217-218
Amsacrine with high-dose cytarabine is effective therapy for Philadelphia chromosome (Ph1)-negative acute lymphoblastic leukemia (ALL). We examined the effectiveness of this regimen in 19 patients with Ph1-positive lymphoblastic leukemia. Four had an antecedent chronic phase of chronic myelogenous leukemia and 15 presented with ALL. There were no complete responders in either group. All 14 patients whose bone marrow could be assessed after completion of therapy showed persistent leukemia. We conclude that patients with Ph1-positive lymphoblastic leukemia have a disease that is resistant to treatment that is highly effective in patients with Ph1-negative ALL. 相似文献
128.
Prenatal cytogenetic diagnosis of the fragile X syndrome in amniotic fluid: calculation of accuracy.
We have completed over 350 prenatal diagnoses for the fragile X [fra(X)] syndrome using amniotic fluid, chorion villus specimen (CVS), fetal blood sampling and molecular methods. A total of 300 amniotic fluid specimens have been received for prenatal diagnosis of the fra(X) syndrome. There was a documented family history of fra(X) in 170/300 amniotic fluid cases, and 23/170 were correctly identified as cytogenetically fra(X) positive (16 male; 7 female). Three males were false-negative, and one female was fra(X) negative but identified as a probable carrier by RFLPs. No fra(X) positive or false-negative results were found in the absence of a fra(X) family history. Because the a priori risk for the fra(X) syndrome for each pregnancy was different and widely variable, the determination of the accuracy of the prenatal diagnosis results requires a consideration of these variables. On this basis, the calculated accuracy of prenatal cytogenetic diagnosis for the fra(X) syndrome is approximately 97%. This accuracy can be improved further with the simultaneous use of molecular methods, especially in view of recent developments. 相似文献
129.
130.
R W Dunn D M Flanagan L L Martin L L Kerman A T Woods F Camacho C A Wilmot M L Cornfeldt R C Effland P L Wood 《European journal of pharmacology》1992,214(2-3):207-214
Anxiolytic agents disinhibit suppressed behaviors in rodents in preclinical models of anxiety such as the non-conditioned social interaction and elevated plus maze assays and the conditioned conflict Cook and Davidson procedure. The (+) and (-) enantiomers of (+/-)-3-amino-1-hydroxy-2-pyrrolidinone (HA-966) have been resolved and revealed that R-(+)-HA-966 significantly disinhibits both non-conditioned and conditioned suppressed behavior similar to the benzodiazepine diazepam, while the S-(-) enantiomer was devoid of anxiolytic activity and only produced behavioral sedation. Furthermore, R-(+)-HA-966 lacked side-effects in rodents commonly associated with the administration of benzodiazepines such as motor incoordination and ataxia, significant interactions with ethanol, and amnesia. These data suggest that R-(+)-HA-966, an antagonist at the strychnine-insensitive glycine/NMDA receptor site, was anxioselective and lacked some of the side-effects associated with benzodiazepine anxiolytics. 相似文献